Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Evercore ISI Downgrades Carisma Therapeutics Inc (CARM) to In Line
December 11, 2024 9:02 AM ESTEvercore ISI analyst Liisa Bayko downgraded Carisma Therapeutics Inc (NASDAQ: CARM) from Outperform to In Line with a price target of $0.70 (from $4.00).
The analyst comments "With the 2nd major pipeline shift this year, scrapping first the macrophage and now the monocyte ex-vivo anti-HER2 program, CARM is focusing on in vivo CAR-M for liver fibrosis while collaborating... More
